Outlook remains cautious for 2006

The past five years have been tough for the large European fine chemicals companies, as the competition from Asia has increased in scope and in quality. The fortune of Active pharmaceutical ingredients (APIs) producers are tied primarily to those of drug developers, a group that has been under severe pressure, and business from the major drug companies has waned. Active pharmaceutical ingredients producers are seeing their overcapacity problems exacerbated by declining product volumes.